Chinese General Practice ›› 2023, Vol. 26 ›› Issue (18): 2262-2267.DOI: 10.12114/j.issn.1007-9572.2022.0892
Special Issue: 肿瘤最新文章合辑; 消化系统疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:
2022-10-28
Revised:
2023-01-20
Published:
2023-06-20
Online:
2023-01-31
Contact:
WU Xin'ai
通讯作者:
吴欣爱
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0892
组别 | 例数 | 性别 | 年龄 | ECOG PS评分 | 原发部位 | |||||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | <60岁 | ≥60岁 | 0分 | 1分 | 左半结直肠 | 右半结直肠 | |||
呋喹替尼单药组 | 28 | 13(46.4) | 15(53.6) | 19(67.9) | 9(32.1) | 11(39.3) | 17(60.7) | 20(71.4) | 8(28.6) | |
PD-1抑制剂联合呋喹替尼组 | 47 | 29(61.7) | 18(38.3) | 37(78.7) | 10(21.3) | 15(31.9) | 32(68.1) | 27(57.4) | 20(42.6) | |
χ2值 | 1.661 | 1.095 | 0.421 | 1.466 | ||||||
P值 | 0.197 | 0.295 | 0.516 | 0.266 | ||||||
组别 | 病理分化程度 | 肝转移 | 肺转移 | 原发病灶切除 | ||||||
高分化腺癌 | 中分化腺癌 | 低分化腺癌 | 是 | 否 | 是 | 否 | 是 | 否 | ||
呋喹替尼单药组 | 2(7.1) | 19(67.9) | 7(25.0) | 19(67.9) | 9(32.1) | 13(46.4) | 15(53.6) | 23(82.1) | 5(17.9) | |
PD-1抑制剂联合呋喹替尼组 | 4(8.5) | 35(74.5) | 8(17.0) | 26(55.3) | 21(44.7) | 20(42.6) | 27(57.4) | 38(80.9) | 9(19.1) | |
χ2值 | 0.811 | 1.149 | 0.107 | 0.019 | ||||||
P值 | 0.729 | 0.284 | 0.744 | 0.890 | ||||||
组别 | MSI状态 | 化疗线数 | KRAS | BRAF | ||||||
MSS | MSI-H | 二线 | 二线以上 | 突变型 | 野生型 | 未知 | 突变型 | 野生型 | 未知 | |
呋喹替尼单药组 | 28(100.0) | 0 | 15(53.6) | 13(46.4) | 10(35.7) | 15(53.6) | 3(10.7) | 2(7.1) | 23(82.1) | 3(10.7) |
PD-1抑制剂联合呋喹替尼组 | 45(95.7) | 2(4.3) | 22(46.8) | 25(53.2) | 18(38.3) | 24(51.1) | 5(10.6) | 7(14.9) | 34(72.3) | 6(12.8) |
χ2值 | — | 0.321 | 0.142 | 1.060 | ||||||
P值 | 0.526 | 0.571 | 1.000 | 0.717 |
Table 1 Comparison of baseline information between the two groups
组别 | 例数 | 性别 | 年龄 | ECOG PS评分 | 原发部位 | |||||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | <60岁 | ≥60岁 | 0分 | 1分 | 左半结直肠 | 右半结直肠 | |||
呋喹替尼单药组 | 28 | 13(46.4) | 15(53.6) | 19(67.9) | 9(32.1) | 11(39.3) | 17(60.7) | 20(71.4) | 8(28.6) | |
PD-1抑制剂联合呋喹替尼组 | 47 | 29(61.7) | 18(38.3) | 37(78.7) | 10(21.3) | 15(31.9) | 32(68.1) | 27(57.4) | 20(42.6) | |
χ2值 | 1.661 | 1.095 | 0.421 | 1.466 | ||||||
P值 | 0.197 | 0.295 | 0.516 | 0.266 | ||||||
组别 | 病理分化程度 | 肝转移 | 肺转移 | 原发病灶切除 | ||||||
高分化腺癌 | 中分化腺癌 | 低分化腺癌 | 是 | 否 | 是 | 否 | 是 | 否 | ||
呋喹替尼单药组 | 2(7.1) | 19(67.9) | 7(25.0) | 19(67.9) | 9(32.1) | 13(46.4) | 15(53.6) | 23(82.1) | 5(17.9) | |
PD-1抑制剂联合呋喹替尼组 | 4(8.5) | 35(74.5) | 8(17.0) | 26(55.3) | 21(44.7) | 20(42.6) | 27(57.4) | 38(80.9) | 9(19.1) | |
χ2值 | 0.811 | 1.149 | 0.107 | 0.019 | ||||||
P值 | 0.729 | 0.284 | 0.744 | 0.890 | ||||||
组别 | MSI状态 | 化疗线数 | KRAS | BRAF | ||||||
MSS | MSI-H | 二线 | 二线以上 | 突变型 | 野生型 | 未知 | 突变型 | 野生型 | 未知 | |
呋喹替尼单药组 | 28(100.0) | 0 | 15(53.6) | 13(46.4) | 10(35.7) | 15(53.6) | 3(10.7) | 2(7.1) | 23(82.1) | 3(10.7) |
PD-1抑制剂联合呋喹替尼组 | 45(95.7) | 2(4.3) | 22(46.8) | 25(53.2) | 18(38.3) | 24(51.1) | 5(10.6) | 7(14.9) | 34(72.3) | 6(12.8) |
χ2值 | — | 0.321 | 0.142 | 1.060 | ||||||
P值 | 0.526 | 0.571 | 1.000 | 0.717 |
不良事件 | 呋喹替尼单药组(n=28) | PD-1抑制剂联合呋喹替尼组(n=47) | χ2值 | P值 |
---|---|---|---|---|
高血压 | 9(32.1) | 14(29.8) | 0.046 | 0.831 |
腹泻 | 5(17.9) | 7(14.9) | 0.115 | 0.735 |
便秘 | 4(14.3) | 11(23.4) | 0.912 | 0.340 |
乏力 | 7(25.0) | 15(31.9) | 0.405 | 0.525 |
恶心和呕吐 | 6(21.4) | 8(17.0) | 0.224 | 0.636 |
白细胞减少 | 8(28.6) | 10(21.3) | 0.512 | 0.474 |
中性粒细胞减少 | 4(14.3) | 6(12.8) | 0 | 1.000 |
血小板减少 | 8(28.6) | 13(27.7) | 0.007 | 0.932 |
贫血 | 10(35.7) | 17(36.2) | 0.002 | 0.968 |
转氨酶升高 | 10(35.7) | 15(31.9) | 0.114 | 0.736 |
胆红素升高 | 5(17.9) | 7(14.9) | 0.115 | 0.735 |
肌酐升高 | 1(3.6) | 4(8.5) | — | 0.645 |
蛋白尿 | 7(25.0) | 10(21.3) | 0.139 | 0.709 |
血尿 | 3(10.7) | 10(21.3) | 0.728 | 0.393 |
高脂血症 | 6(21.4) | 9(19.1) | 0.057 | 0.811 |
心肌酶升高 | 2(7.1) | 2(4.3) | — | 0.626 |
口腔黏膜炎 | 3(10.7) | 2(4.3) | — | 0.356 |
手足综合征 | 6(21.4) | 10(21.3) | 0 | 0.988 |
皮疹 | 4(14.3) | 6(12.8) | 0 | 1.000 |
甲状腺功能减退 | 5(17.9) | 19(40.4) | 4.107 | 0.043 |
间质性肺炎 | 0 | 2(4.3) | — | 0.526 |
声音嘶哑 | 0 | 2(4.3) | — | 0.526 |
Table 2 Comparison of all adverse reactions during treatment between the two groups
不良事件 | 呋喹替尼单药组(n=28) | PD-1抑制剂联合呋喹替尼组(n=47) | χ2值 | P值 |
---|---|---|---|---|
高血压 | 9(32.1) | 14(29.8) | 0.046 | 0.831 |
腹泻 | 5(17.9) | 7(14.9) | 0.115 | 0.735 |
便秘 | 4(14.3) | 11(23.4) | 0.912 | 0.340 |
乏力 | 7(25.0) | 15(31.9) | 0.405 | 0.525 |
恶心和呕吐 | 6(21.4) | 8(17.0) | 0.224 | 0.636 |
白细胞减少 | 8(28.6) | 10(21.3) | 0.512 | 0.474 |
中性粒细胞减少 | 4(14.3) | 6(12.8) | 0 | 1.000 |
血小板减少 | 8(28.6) | 13(27.7) | 0.007 | 0.932 |
贫血 | 10(35.7) | 17(36.2) | 0.002 | 0.968 |
转氨酶升高 | 10(35.7) | 15(31.9) | 0.114 | 0.736 |
胆红素升高 | 5(17.9) | 7(14.9) | 0.115 | 0.735 |
肌酐升高 | 1(3.6) | 4(8.5) | — | 0.645 |
蛋白尿 | 7(25.0) | 10(21.3) | 0.139 | 0.709 |
血尿 | 3(10.7) | 10(21.3) | 0.728 | 0.393 |
高脂血症 | 6(21.4) | 9(19.1) | 0.057 | 0.811 |
心肌酶升高 | 2(7.1) | 2(4.3) | — | 0.626 |
口腔黏膜炎 | 3(10.7) | 2(4.3) | — | 0.356 |
手足综合征 | 6(21.4) | 10(21.3) | 0 | 0.988 |
皮疹 | 4(14.3) | 6(12.8) | 0 | 1.000 |
甲状腺功能减退 | 5(17.9) | 19(40.4) | 4.107 | 0.043 |
间质性肺炎 | 0 | 2(4.3) | — | 0.526 |
声音嘶哑 | 0 | 2(4.3) | — | 0.526 |
不良事件 | 呋喹替尼单药组(n=28) | PD-1抑制剂联合呋喹替尼组(n=47) | χ2值 | P值 |
---|---|---|---|---|
高血压 | 3(10.7) | 5(10.6) | 0 | 1.000 |
白细胞减少 | 1(3.6) | 3(6.4) | — | 1.000 |
中性粒细胞减少 | 0 | 2(4.3) | — | 0.526 |
血小板减少 | 3(10.7) | 1(2.1) | — | 0.285 |
贫血 | 2(7.1) | 2(4.3) | — | 0.994 |
转氨酶升高 | 1(3.6) | 2(4.3) | — | 1.000 |
肌酐升高 | 0 | 1(2.1) | — | 1.000 |
蛋白尿 | 1(3.6) | 1(2.1) | — | 1.000 |
手足综合征 | 2(10.7) | 2(4.3) | — | 0.994 |
Table 3 Comparison of adverse reactions of grade 3 and above during treatment between the two groups
不良事件 | 呋喹替尼单药组(n=28) | PD-1抑制剂联合呋喹替尼组(n=47) | χ2值 | P值 |
---|---|---|---|---|
高血压 | 3(10.7) | 5(10.6) | 0 | 1.000 |
白细胞减少 | 1(3.6) | 3(6.4) | — | 1.000 |
中性粒细胞减少 | 0 | 2(4.3) | — | 0.526 |
血小板减少 | 3(10.7) | 1(2.1) | — | 0.285 |
贫血 | 2(7.1) | 2(4.3) | — | 0.994 |
转氨酶升高 | 1(3.6) | 2(4.3) | — | 1.000 |
肌酐升高 | 0 | 1(2.1) | — | 1.000 |
蛋白尿 | 1(3.6) | 1(2.1) | — | 1.000 |
手足综合征 | 2(10.7) | 2(4.3) | — | 0.994 |
[1] |
|
[2] |
中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠外科学组,中国抗癌协会大肠癌专业委员会,等. 中国结直肠癌肝转移诊断和综合治疗指南(2018版)[J]. 中国实用外科杂志,2018,38(7):707-718. DOI:10.19538/j.cjps.issn1005-2208.2018.07.03.
|
[3] |
中国结直肠癌诊疗规范(2020年版)专家组. 国家卫生健康委员会中国结直肠癌诊疗规范(2020年版)[J]. 中华胃肠外科杂志,2020(6):521-540.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
体能状态评分ECOG评分法[J].中华普通外科学文献(电子版),2012,6(6):556.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[1] | HU Jieman, TAN Feixiang, YUAN Anxin, CHEN Shiyu, TANG Chulei, YIN Yueheng, BA Lei, XU Qin. Analysis of the Trajectory of Postoperative Frailty and Influencing Factors in Patients with Colorectal Cancer [J]. Chinese General Practice, 2025, 28(26): 3276-3282. |
[2] | WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940. |
[3] | MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685. |
[4] | ADILI Tuersun, CHENG Gang. Meta-analysis of the Efficacy and Safety of Finerenone in the Treatment of Type 2 Diabetic Nephropathy [J]. Chinese General Practice, 2025, 28(21): 2686-2691. |
[5] | LIU Caiping, ZHANG Yanhua, TANG Jianpin, WANG Chengpeng, XUE Fengfeng, WANG Huijuan, LI Chuanwei, ZHANG Guangya, LI Huafang. Efficacy and Safety of Long-acting Risperidone Microspheres in the Maintenance Treatment of Schizophrenia [J]. Chinese General Practice, 2025, 28(13): 1622-1627. |
[6] | SONG Fenfen, LI Shengmian. Real-World Study of Camrelizumab-based Regimen for Locally Advanced and Metastatic Esophageal Cancer [J]. Chinese General Practice, 2025, 28(07): 844-852. |
[7] | ZHOU Jin, WANG Yan, WANG Hui, ZHANG Yinan, ZHI Xiaoxu, ZHANG Zhiyuan, XU Dejing, ZHOU Xin, ZHANG Liuliu. Construction of a Comprehensive Health Management Program for Elderly Postoperative Colorectal Cancer Patients [J]. Chinese General Practice, 2024, 27(21): 2600-2606. |
[8] | BAI Xin, WU Xinyu, ZHAO Zun, LIU Shuxin, LIU Simiao, XUE Yuhang, XU Junling, GAO Yongju. Efficacy Analysis of 131I Therapy in Serum Thyroglobulin Antibody Positive Differentiated Thyroid Carcinoma with Distant Metastasis [J]. Chinese General Practice, 2024, 27(15): 1833-1837. |
[9] | NIU Jingyuan, CHEN Huisheng, YU Jiaxiang, CUI Yu. Ligustrazine Injection in the Treatment of Acute Ischemic Stroke: a Bayesian Network Meta-analysis [J]. Chinese General Practice, 2024, 27(14): 1761-1774. |
[10] | RAN Dongsheng, LU Yanyan, XIN Chunling, MA Yingcai. Research Progress on the Correlation of Dyslipidemia with Colorectal Serrated Lesions and Colorectal Cancer [J]. Chinese General Practice, 2024, 27(12): 1424-1430. |
[11] | CHEN Dan, WANG Yawei, HUANG Fang, XU Yifan, ZHANG Yiying, SHAO Yueqin. Epidemic Trend Analysis of Colorectal Cancer in Jiading District, Shanghai from 2003 to 2019 [J]. Chinese General Practice, 2024, 27(10): 1261-1266. |
[12] | FENG Zhengwen, CHEN Xiaolei, LI Hui, ZHU Chenli, SHAO Shuang, DU Juan. Preliminary Development of Self-assessment Scale for the Ability of Outpatients with Chronic Diseases to Participate in Medication Safety Based on the Delphi Method [J]. Chinese General Practice, 2024, 27(05): 604-611. |
[13] | ZHANG Yisheng, TANG Fubo, SUN Yaru, ZHONG Yuanming, LI Zhifei. Clinical Efficacy of Percutaneous Endoscopic Posterior Tranforaminal Lumbar Interbody Fusion Combined with Height Adjustable Titanium Fusion Cage in the Treatment of Lumbar Spondylolisthesis with Lumbar Spinal Stenosis [J]. Chinese General Practice, 2023, 26(35): 4464-4471. |
[14] | ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822. |
[15] | HUANG Dan, ZHANG Qihan, SONG Ge, WANG Qing, LI Yu, JI Xunming, WANG Yuan. Efficacy and Safety of Intermittent Hypoxic Training in the Prevention of Acute Hypoxic Injury [J]. Chinese General Practice, 2023, 26(29): 3640-3644. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||